Institute for Brain Science and Technology (IBST)/Graduate Program in Neuroscience, Inje University, Busan 614-735, Korea.
Exp Neurobiol. 2010 Dec;19(3):120-31. doi: 10.5607/en.2010.19.3.120. Epub 2010 Dec 31.
Alzheimer's disease, the most common cause of dementia, is characterized by two major pathological hallmarks: amyloid plaques and neurofibrillary tangles. Based on these two indicators, an amyloid cascade hypothesis was proposed, and accordingly, most current therapeutic approaches are now focused on the removal of β-amyloid peptides (Aβ from the brain. Additionally, strategies for blocking tau hyperphosphorylation and aggregation have been suggested, including the development of drugs that can block the formation of tangles. However, there are no true disease-modifying drugs in the current market, though many drugs based on theories other than Aβ and tau pathology are under development. The purpose of this review was to provide information on the current development of AD drugs and to discuss the issues related to drug development.
阿尔茨海默病是痴呆症最常见的病因，其特征是存在两种主要的病理学特征：淀粉样斑块和神经纤维缠结。基于这两个指标，提出了淀粉样蛋白级联假说，因此，目前大多数治疗方法都集中在清除大脑中的β-淀粉样肽（Aβ）上。此外，还提出了阻止 tau 过度磷酸化和聚集的策略，包括开发可以阻止缠结形成的药物。然而，目前市场上没有真正的疾病修饰药物，尽管有许多基于 Aβ 和 tau 病理学以外的理论的药物正在开发中。本综述的目的是提供有关 AD 药物开发现状的信息，并讨论与药物开发相关的问题。
